International Journal of Hematology

, Volume 107, Issue 6, pp 696–702 | Cite as

Favorable survival in lung transplant recipients on preoperative low-dose, as compared to high-dose corticosteroids, after hematopoietic stem cell transplantation

  • Seiichiro Sugimoto
  • Kentaroh Miyoshi
  • Takeshi Kurosaki
  • Shinji Otani
  • Masaomi Yamane
  • Motomu Kobayashi
  • Takahiro Oto
Original Article


Although the number of patients developing pulmonary complications after hematopoietic stem cell transplantation (HSCT) necessitating lung transplantation (LT) is increasing, a little information is available about factors influencing the prognosis after LT in these patients. Corticosteroids represent the first-line therapy for pulmonary complications after HSCT; however, prolonged corticosteroid treatment prior to LT increases the potential risks of LT. In this study, we assessed the effect of preoperative corticosteroid therapy on long-term survival in patients undergoing LT after HSCT. We retrospectively investigated data from 13 patients who had received high-dose corticosteroid therapy and nine who had received low-dose corticosteroid therapy prior to LT for pulmonary complications after HSCT. Other than the preoperative corticosteroid dose, patient clinical characteristics did not differ. The incidence of postoperative complications within the first year after LT was significantly lower in the low-dose corticosteroid group (p = 0.026). Survival after LT was also significantly better in the low-dose corticosteroid group than in the high-dose corticosteroid group (p = 0.034). In recipients of LT after HSCT, preoperative low-dose corticosteroid use, as compared to preoperative high-dose corticosteroid use, could limit the risks of postoperative complications developing within the first year after the LT, leading to improved long-term survival after LT.


Lung transplantation Hematopoietic stem cell transplantation Steroid Survival 



This work was supported by a Grant-in-Aid for Scientific Research (Grant no. 15K10256) from the Japan Society for the Promotion of Science.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Yusen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1170–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Yamane M, Sano Y, Toyooka S, Okazaki M, Date H, Oto T. Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. Transplantation. 2008;86:1767–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen F, Yamane M, Inoue M, Shiraishi T, Oto T, Minami M, et al. Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. Am J Transplant. 2011;11:1509–16.CrossRefPubMedGoogle Scholar
  7. 7.
    Vogl UM, Nagayama K, Bojic M, Hoda MA, Klepetko W, Jaksch P, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation. 2013;95:623–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheng GS, Edelman JD, Madtes DK, Martin PJ, Flowers ME. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1169–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen-Yoshikawa TF, Sugimoto S, Shiraishi T, Minami M, Matsuda Y, Chida M, et al. Prognostic factors in lung transplantation after hematopoietic stem cell transplantation. Transplantation. 2018;102:154–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Weder W, Inci I, Korom S, Kestenholz PB, Hillinger S, Eich C, et al. Airway complications after lung transplantation: risk factors, prevention and outcome. Eur J Cardiothorac Surg. 2009;35:293–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant. 2014;14:438–45.CrossRefPubMedGoogle Scholar
  12. 12.
    McAnally KJ, Valentine VG, LaPlace SG, McFadden PM, Seoane L, Taylor DE. Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant. 2006;25:67–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Calhoon JH, Levine S, Anzueto A, Bryan CL, Trinkle JK. Lung transplantation in a patient with a prior bone marrow transplant. Chest. 1992;102:948.CrossRefPubMedGoogle Scholar
  14. 14.
    Rabitsch W, Deviatko E, Keil F, Herold C, Dekan G, Greinix HT, et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation. 2001;71:1341–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann Thorac Surg. 2005;79:1051–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33:127–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360:2328–39.CrossRefPubMedGoogle Scholar
  18. 18.
    Date H, Sato M, Aoyama A, Yamada T, Mizota T, Kinoshita H, et al. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients. Eur J Cardiothorac Surg. 2015;47:967–73.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Department of General Thoracic SurgeryOkayama University HospitalOkayamaJapan
  2. 2.Department of Organ Transplant CenterOkayama University HospitalOkayamaJapan
  3. 3.Department of Anesthesiology and ResuscitologyOkayama University HospitalOkayamaJapan

Personalised recommendations